TCM Biotech International Corp. (TPE:4169)

Market Cap	15.94B +391.8%
Revenue (ttm)	703.09M +7.0%
Net Income	-13.80M
EPS	-0.24
Shares Out	59.05M
PE Ratio	n/a
Forward PE	300.81
Dividend	0.36 (0.13%)
Ex-Dividend Date	Jul 20, 2026

Volume	829,824
Open	282.50
Previous Close	279.00
Day's Range	262.50 - 284.00
52-Week Range	58.00 - 288.00
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4169

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 9, 2026

Data Sources Report a data error